284 related articles for article (PubMed ID: 32633419)
1. MHC class I transactivator NLRC5 in host immunity, cancer and beyond.
Cho SX; Vijayan S; Yoo JS; Watanabe T; Ouda R; An N; Kobayashi KS
Immunology; 2021 Mar; 162(3):252-261. PubMed ID: 32633419
[TBL] [Abstract][Full Text] [Related]
2. Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.
Vijayan S; Sidiq T; Yousuf S; van den Elsen PJ; Kobayashi KS
Immunogenetics; 2019 Mar; 71(3):273-282. PubMed ID: 30706093
[TBL] [Abstract][Full Text] [Related]
3. NLRC5: a newly discovered MHC class I transactivator (CITA).
Meissner TB; Li A; Kobayashi KS
Microbes Infect; 2012 Jun; 14(6):477-84. PubMed ID: 22209772
[TBL] [Abstract][Full Text] [Related]
4. FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA.
Kasuga Y; Ouda R; Watanabe M; Sun X; Kimura M; Hatakeyama S; Kobayashi KS
Proc Natl Acad Sci U S A; 2023 Jun; 120(24):e2218955120. PubMed ID: 37279268
[TBL] [Abstract][Full Text] [Related]
5. Regulation of class I major histocompatibility complex (MHC) by nucleotide-binding domain, leucine-rich repeat-containing (NLR) proteins.
Robbins GR; Truax AD; Davis BK; Zhang L; Brickey WJ; Ting JP
J Biol Chem; 2012 Jul; 287(29):24294-303. PubMed ID: 22645137
[TBL] [Abstract][Full Text] [Related]
6. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
7. NLRC5: a key regulator of MHC class I-dependent immune responses.
Kobayashi KS; van den Elsen PJ
Nat Rev Immunol; 2012 Dec; 12(12):813-20. PubMed ID: 23175229
[TBL] [Abstract][Full Text] [Related]
8. Emerging Major Histocompatibility Complex Class I-Related Functions of NLRC5.
Chelbi ST; Dang AT; Guarda G
Adv Immunol; 2017; 133():89-119. PubMed ID: 28215281
[TBL] [Abstract][Full Text] [Related]
9. The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression.
Neerincx A; Jakobshagen K; Utermöhlen O; Büning H; Steimle V; Kufer TA
J Immunol; 2014 Sep; 193(6):3090-100. PubMed ID: 25127861
[TBL] [Abstract][Full Text] [Related]
10. The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.
Shukla A; Cloutier M; Appiya Santharam M; Ramanathan S; Ilangumaran S
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671123
[TBL] [Abstract][Full Text] [Related]
11. LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.
Zhan L; Zhang J; Zhang J; Liu X; Zhu S; Shi Y; He Y; Wang W; Fan Y; Tang Z; Chen G; Wei B; Cao Y
Cancer Lett; 2022 Mar; 529():37-52. PubMed ID: 34974132
[TBL] [Abstract][Full Text] [Related]
12. The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity.
Meissner TB; Li A; Liu YJ; Gagnon E; Kobayashi KS
Biochem Biophys Res Commun; 2012 Feb; 418(4):786-91. PubMed ID: 22310711
[TBL] [Abstract][Full Text] [Related]
13. CITA/NLRC5: A critical transcriptional regulator of MHC class I gene expression.
Downs I; Vijayan S; Sidiq T; Kobayashi KS
Biofactors; 2016 Jul; 42(4):349-57. PubMed ID: 27087581
[TBL] [Abstract][Full Text] [Related]
14. NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens.
Yao Y; Wang Y; Chen F; Huang Y; Zhu S; Leng Q; Wang H; Shi Y; Qian Y
Cell Res; 2012 May; 22(5):836-47. PubMed ID: 22491475
[TBL] [Abstract][Full Text] [Related]
15. Expression regulation and function of NLRC5.
Yao Y; Qian Y
Protein Cell; 2013 Mar; 4(3):168-75. PubMed ID: 23483478
[TBL] [Abstract][Full Text] [Related]
16. The MHC Class II Transactivator CIITA: Not (Quite) the Odd-One-Out Anymore among NLR Proteins.
León Machado JA; Steimle V
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499042
[TBL] [Abstract][Full Text] [Related]
17. NLRC5/MHC class I transactivator: A key target for immune escape by SARS-CoV-2.
Zhu B; Ouda R; Kasuga Y; de Figueiredo P; Kobayashi KS
Bioessays; 2024 Apr; 46(4):e2300109. PubMed ID: 38461519
[TBL] [Abstract][Full Text] [Related]
18. NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers.
Ong CEB; Patchett AL; Darby JM; Chen J; Liu GS; Lyons AB; Woods GM; Flies AS
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1973-1991. PubMed ID: 33797607
[TBL] [Abstract][Full Text] [Related]
19. NLRC5 controls basal MHC class I gene expression in an MHC enhanceosome-dependent manner.
Neerincx A; Rodriguez GM; Steimle V; Kufer TA
J Immunol; 2012 May; 188(10):4940-50. PubMed ID: 22490867
[TBL] [Abstract][Full Text] [Related]
20. Cutting edge: impaired MHC class I expression in mice deficient for Nlrc5/class I transactivator.
Biswas A; Meissner TB; Kawai T; Kobayashi KS
J Immunol; 2012 Jul; 189(2):516-20. PubMed ID: 22711889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]